First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report

E. Amabile; F. Fazio; M. Martelli; MT. Petrucci

Leukemia Research Reports (Jan 2024)

First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report

E. Amabile,
F. Fazio,
M. Martelli,
MT. Petrucci

Affiliations

E. Amabile: Corresponding author.; Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Azienda Policlinico Umberto I, Rome, Italy
F. Fazio: Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Azienda Policlinico Umberto I, Rome, Italy
M. Martelli: Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Azienda Policlinico Umberto I, Rome, Italy
MT. Petrucci: Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Azienda Policlinico Umberto I, Rome, Italy

Journal volume & issue: Vol. 22
p. 100491

Abstract

Read online

POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M–protein, skin changes syndrome) is a rare condition due to an underlying plasma cell neoplasm whose clinical presentation can be various so it could lead to delayed diagnosis and treatment. The pathogenesis of the syndrome is not well understood, and its therapy is adapted from other plasma cell disorders with the aim of alleviating symptoms, decreasing end-organ damage, improving quality of life and prolonging overall survival. We report a case of a 71 years-old woman who has been treated with continuous DRd (daratumumab, lenalidomide and dexamethasone) scheme.

Published in Leukemia Research Reports

ISSN: 2213-0489 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.journals.elsevier.com/leukemia-research-reports/

About the journal

Abstract

Keywords